Background: In multiple myeloma (MM), impact of specific chromosomal translocations involving IgH (14q21 locus, including t(4;14), t(11;14), and t(14;16)) has been explored extensively. However, over 15% MM patients harboring IgH translocation with undefined partners have long been ignored.
Methods: A prospective non-randomized cohort study with a total of 715 newly-diagnosed MM cases was conducted, 13.6% of whom were t(14;undefined) positive. The whole cohort was divided into four groups: no IgH split (47.7%); t(14;undefined) (13.6%); t(11;14) (17.6%); and t(4;14) or t(14;16) group (21.1%).
Results: Median OS for the four groups was 84.2, not reached (NR), 58.7, and 44.2 months, respectively, with P values for t(14;undefined) vs no IgH split, t(11;14), and t(4;14)/t(14;16) groups of 0.197, 0.022, and 0.001, respectively. In bortezomib-based group, the survival advantage gained by t(14;undefined) group was much more significant compared to t(11;14) and t(4;14)/t(14;16) groups. Importantly, t(14;undefined) turned out to be an independent predictive factor for longer OS of MM patients in multivariate analysis, especially in the context of bortezomib treatment. Similar results were also observed in the PUMCH external validation cohort.
Conclusion: Collectively, our data confirmed and externally validated the favorable prognosis of the t(14;undefined) groups, especially in the era of novel agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ejh.13440 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Burkitt lymphoma.
Hum Pathol
December 2024
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:
Burkitt lymphoma is a mature aggressive B-cell neoplasm with distinctive clinical and morphologic features, a germinal center B-cell immunophenotype, a high proliferation index and MYC rearrangement with an immunoglobulin gene partner. Initially described in equatorial Africa by a surgeon, Denis Burkitt, African (endemic) Burkitt lymphoma was the first neoplasm shown to be associated with a virus, Epstein-Barr virus (EBV), and the first neoplasm shown to be associated with a chromosomal translocation, IGH::MYC. In this article, we provide a brief historical introduction of Burkitt lymphoma, followed by a review of all aspects of this neoplasm including pathogenesis, clinical presentation, morphology, immunophenotype, cytogenetics and molecular findings.
View Article and Find Full Text PDFPrimary Gastric Atypical Burkitt Lymphoma: A Rare Case Report.
J Investig Med High Impact Case Rep
November 2024
Division of Hematology/Oncology, Brookdale University Hospital Medical Center, Brooklyn, NY, USA.
Article Synopsis
- Sporadic Burkitt lymphoma (BL) usually affects the abdomen, especially the ileocecal area, while stomach involvement is extremely rare.
- This case report highlights a unique instance of atypical Burkitt lymphoma that originated in the stomach, which has not been previously documented.
- Diagnostic tests showed positive markers like CD20 and the c-MYC gene rearrangement, but the common translocations related to Burkitt lymphoma were not present.
Increased c-MYC Expression Associated with Active IGH Locus Rearrangement: An Emerging Role for c-MYC in Chronic Lymphocytic Leukemia.
Cancers (Basel)
November 2024
Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR) 7276/INSERM U1262, Université de Limoges, 87000 Limoges, France.
Article Synopsis
- * Its overexpression is particularly linked to CLL cases with unmutated immunoglobulin heavy chain variable (IGHV) genes, causing significant DNA damage and contributing to a more aggressive disease.
- * The review emphasizes c-MYC's dual role in promoting rapid cell proliferation and driving genetic recombination, suggesting it could be a promising target for new therapeutic strategies in CLL.
Cyclin D1-negative mantle cell lymphoma.
Hum Pathol
November 2024
Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Cyclin D1-negative mantle cell lymphoma (MCL) is regarded as a B-cell neoplasm that has morphologic and immunophenotypic findings indistinguishable from typical MCL. These neoplasms lack cyclin D1 overexpression by immunohistochemistry and t(11;14)(q13;q32)/IGH::CCND1. Since cyclin D1-negative MCL was first recognized by gene expression profiling in 2003, there has been diagnostic confusion regarding this entity, mostly attributable to a lack of diagnostic tools to recognize these neoplasms in most clinical laboratories.
View Article and Find Full Text PDFMolecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review.
Int J Mol Sci
October 2024
Department of Hematology, Aarhus University Hospital, 8200 Aarhus N, Denmark.
Article Synopsis
- Follicular lymphoma (FL) is a common type of slow-growing B-cell lymphoma characterized by the t(14;18) translocation and presents a diverse range of clinical outcomes, with most patients initially having a favorable prognosis but facing incurable relapses and potential transformation to aggressive forms of lymphoma.
- The review analyzes research on molecular biomarkers related to FL transformation and patient outcomes, examining 283 studies published between January 1984 and September 2024, adhering to PRISMA guidelines.
- It categorizes biomarkers into groups based on their effects on prognosis or transformation risk, identifying various genetic, gene expression, and microRNA markers, while highlighting ongoing challenges in predicting transformation risk for FL patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!